This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Avi Kapoor 1 month ago
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Stifel analyst Brad Reback upgraded Microsoft Corp (NASDAQ:MSFT) from Hold to Buy and raised the price target from $530 to $575. Microsoft closed at $498.00 on Tuesday. See how other analysts view this stock.
- JP Morgan analyst Detlef Winckelmann upgraded Graphic Packaging Holding Co (NYSE:GPK) from Neutral to Overweight and cut the price target from $12.5 to $11.5. Graphic Packaging Holding shares closed at $9.57 on Tuesday. See how other analysts view this stock.
- Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine Inc (NASDAQ:EDIT) from Neutral to Buy and announced a $5 price target. Editas Medicine closed at $2.92 on Tuesday. See how other analysts view this stock.
- RBC Capital analyst Brian Abrahams upgraded Lakefront Biotherapeutics NV – ADR (NASDAQ:LKFT) from Sector Perform to Outperform and raised the price target from $26 to $45. Lakefront Biotherapeutics shares closed at $30.19 on Tuesday. See how other analysts view this stock.
Considering buying EDIT stock? Here’s what analysts think:
Photo via Shutterstock